Send us Feedback

Methylgene Inc (MYG)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
MethylGene Presents Preclinical Data for MGCD265 at the American Association for Cancer Research (AACR) Annual Meeting
Marketwire  Apr 2  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 04/02/12 -- MethylGene Inc. (TSX:MYG) today disclosed preclinical data during a presentation for its proprietary multi-targeted kinase inhibitor, MGCD265, at the 2012 AACR Annual Meeting held in Chicago, Illinois.
MethylGene to Present at the American Association for Cancer Research (AACR) Annual Meeting
Marketwire  Mar 28  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 03/28/12 -- MethylGene Inc. (TSX:MYG) today announced that preclinical data for its multi-targeted kinase inhibitor, MGCD265, will be reported in a poster session at the 2012 American Association for Cancer
MethylGene Announces the Appointment of Dr. Henry J. Fuchs to its Board of Directors
Marketwire  Feb 2  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 02/02/12 -- MethylGene Inc. (TSX:MYG) is pleased to announce the appointment of Dr. Henry J. Fuchs to the Company's Board of Directors. "Dr. Fuchs is a highly regarded leader in the biotechnology industry and
MethylGene Reports Third Quarter 2011 Financial Results and Provides Clinical Update
Marketwire  Nov 3  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 11/03/11 -- MethylGene Inc. (TSX:MYG) today reported financial results for the third quarter ended September 30, 2011. In addition, the Company provided a clinical update for its product candidates MGCD265 and
MethylGene Receives FDA IND Approval to Begin a Phase 2 Clinical Trial With MGCD290, a Novel Antifungal Product Candidate
Marketwire  Oct 18  Comment 
MONTREAL, CANADA -- (Marketwire) -- 10/18/11 -- MethylGene Inc. (TSX:MYG) today announced that it has received approval for its initial Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to start a Phase 2
MethylGene Appoints Joseph Walewicz as Vice President, Business and Corporate Development
Marketwire  Oct 6  Comment 
MONTREAL, CANADA -- (Marketwire) -- 10/06/11 -- MethylGene Inc. (TSX:MYG) today announced the appointment of Mr. Joseph Walewicz as Vice President, Business and Corporate Development. Mr. Walewicz will be leading MethylGene's partnering and investor
MethylGene to Present at Biotech Showcase 2011
Marketwire  Jan 6  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 01/06/11 -- MethylGene Inc. (TSX: MYG), today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer of MethylGene will present an overview of the Company at Biotech Showcase 2011 which will
MethylGene's Lead Program, MGCD265, Nominated "Top Ten Oncology Projects to Watch" by Windhover and Campbell Alliance
Marketwire  Oct 20  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 10/20/10 -- MethylGene Inc. (TSX: MYG) announced today that its lead multi-targeted Met kinase inhibitor for oncology, MGCD265, has been selected by Windhover and Campbell Alliance as one of the "Top 10 Most
MethylGene to Present at BioContact Quebec
Marketwire  Sep 29  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 09/29/10 -- MethylGene Inc. (TSX: MYG), announced today that Mr. Charles Grubsztajn, President and Chief Executive Officer of the Company, will be presenting an overview of MethylGene at BioContact Quebec in Quebec
MethylGene Issued Key Patents for Lead Oncology Program
Marketwire  Sep 28  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 09/28/10 -- MethylGene Inc. (TSX: MYG), announced today that it has been granted two composition of matter patents from the United States Patent and Trademark Office for the Company's multi-targeted (Met) kinase




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Methylgene_Inc_(MYG)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki